Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T-Cell Therapy – Genetic Engineering & Biotechnology News (blog)
BioPharma-Reporter.com |
Cell Medica Acquires Catapult Therapy for Lead WT1-TCR T–Cell Therapy
Genetic Engineering & Biotechnology News (blog) Cell Medica is exploiting its proprietary activated T cell, chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) platforms to develop cellular immotherapies targeting cancer. Lead product CMD-003 (baltaleucel-T) is being evaluated in … Cell and Gene Therapy Catapult Announces Cell Medica Acquisition of WT1 T–cell Therapy Cell Medica Acquires WT1 Cancer Immunotherapy from Cell and Gene Therapy Catapult |
